The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
|
|
- Job Cole
- 5 years ago
- Views:
Transcription
1 De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
2 DISCLOSURE C.O.I. 1. Honorary as speakers from MSD, ViiV, GSK, Gilead, Stendhal, Janssen and Abbvie 2. Honorary in Advisory Boards from MSD, ViiV/GSK, Gilead and Stendhal 3. Research Grants from ViiV/GSK. 4. Financial Support for medical Education foundations and networking from GSK, MSD, Stendhal, Abbvie and Janssen
3 Introudcton of INSTI into practice in the HIV treatment history UCHCC: UNC CFAR HIV Clinical Cohort (University of North Carolina) Percent 100% 90% 80% 70% 60% 50% 40% 30% 20% NRTI Only Initial Antiretroviral Therapy, UCHCC Other (including unboosted and other bpi) NNRTI bpi (LPV/r, DRV/r, ATV/r) 10% INSTI 0% Calendar Year RAL Oct, 2007 Stribild Aug, 2012 Triumeq Aug, 2014 Modified from Joe Eron
4
5
6 A R T 1st World INSTI LATAM
7 WHO, 2013 EACS, 2013 BHIVA, 2013 GESIDA,2014 IAS, 2014 DHHS, 2014 ABC/3TCTDF/FTC EFV NVP RPV/TDF/FTC LPV/r ATV/r FPV/r DRV/r RAL DTG EVG/cobi/ TDF/FTC Otros AZT MVC Preferred Alternative Conditioned ABC/3TCTDF/FTC EFV NVP RPV/TDF/FTC LPV/r ATV/r FPV/r DRV/r RAL DTG EVG/cobi/ Otros WHO, 2015 EFV-400 AZT EACS, 2017 or TAF or ATV/c or DRV/c or STR BHIVA, 2016 or TAF GESIDA,2016 or TAF or ATV/c or DRV/c or STR IAS, 2016 TAF! o DRV/c or STR TAF! DHHS, 2016 o TAF or STR +/- TAF TDF/FTC
8 Country, year AZT/3TCABC/3TC TDF/FTC EFV NVP RPVc LPV/r ATV/r FPV/r DRV/r RAL DTG EVGc Ecuador, 2012 Chile, 2013 Venez, 2014 Colombia,2014 Argent, TDF/F +/- TAF Brazil, TDF/3 +TDF/3 Mexico, 2017 o STR TAF!
9 Country, year AZT/3TCABC/3TC TDF/FTC EFV NVP RPVc LPV/r ATV/r FPV/r DRV/r RAL DTG EVGc Ecuador, 2012 Chile, 2013 Venez, 2014 Colombia,2014 o STR Argent, 2016 STR STR o ATV/c +TDF/F +/- TAF Brazil, DTG +TDF/3 +TDF/3 +TDF/3 Mexico, DTG TAF! o STR STR o ATV/c o STR TAF! Up to 3 year delay in the adoption of new therapies (INSTI, STR, TAF)
10 Comparative efficacy and safety of first-line antiretroviral therapy: a systematic review and network meta-analysis Network of eligible comparisons between treatments Kanters S., et al. Lancet HIV 2016; 3: e510 20
11 Kanters S., et al. Lancet HIV 2016; 3: e510 20
12 Kanters S., et al. Lancet HIV 2016; 3: e510 20
13 Late presentation by age in L Am 80,0% 70,0% 60,0% 50,0% 40,0% 30,0% 20,0% 10,0% 0,0% < > >69 Beltran C, et al. HIV Hepatitis Americas Brazil P042
14 ART options Risk of DDI IP/r, Cobi RAL, DTG, RPV ABC, LPV, FPV, EFV CVD IP/r, Cobi RAL, DTG, TDF, RPV, LPV, FPV, EFV RAL, DTG ABC, LPV, FPV, EFV Cancer Lipid Dis. IP/r, Cobi TDF/FTC, 3TC, ABC, RAL, DTG, NVP, LPV, EFV IP/r, Cobi HBV, HCV Coinf. TB Coinf. EFV, RAL, TDF, ABC, NVP, DTG IP/r, RPV RAL, ABC, TDF, ATV, LPV IP/r, Cobi, DTG, RPV Renal Dysfn RAL, DTG ABC, IP/r Bone metab. HAND IP/r, Cobi, EFV RAL, DTG, DRV, MVC, EFV, TDF, LPV IP/r, Cobi
15 CVD Lipid Dis.
16 Martinez E., et al. AIDS 2012, 26: CVD Lipid Dis.
17 Martinez E., et al. AIDS 2012, 26: CVD Lipid Dis.
18 CVD Lipid Dis.
19 CVD
20 TB Coinf. Grinsztejn B, et al., ANRS Reflate TB study group. Lancet Infect Dis Jun;14(6):459-67
21 HAND Raltegravir Concentrations in Cerebrospinal Fluid RAL concentrations in CSF exceeded the IC50 for wild-type HIV in all specimens by a median of 4.5-fold. Croteau D., et al. Antimicrob Agents and Chemther, Dec. 2010, p Letendre S., Top Antivir Med November ; 19(4):
22 HAND Dolutegravir Concentrations in Plasma and Cerebrospinal Fluid The DTG concentrations in CSF were similar to unbound plasma concentrations and exceeded the in vitro 50% inhibitory concentration for wild-type HIV (0.2 ng/ml), suggesting that DTG achieves therapeutic concentrations in the central nervous system. The HIV-1 RNA reductions were similar in CSF and plasma Letendre S., et al. Clinical Infectious Diseases 2014;59(7):1032 7
23 Bone metab. RAL + TDF/FTC (n = 603), ATV/RTV + TDF/FTC (n = 605), or DRV/RTV + TDF/FTC (n = 601) All arms associated with significant loss of BMD through Wk 96 (P <.001) At hip and spine, similar loss of BMD in the PI arms Significantly greater loss in the combined PI arms than in the RAL arm Loss of BMD (%) Total Hip P = P =.005 Total Spine P = P <.001 ATV/RTV + TDF/FTC RAL + TDF/FTC DRV/RTV + TDF/FTC Combined PI arms Brown TT, et al. J Infect Dis. 2015;[Epub ahead of print].
24 SINGLE: bone turnover markers Bone metab. Greater change in bone turnover markers for Efavirenz(TDF/FTC vs Dolutegravir/ABC/3TC in antiretroviral therapy-naive adults over 144 weeks Tebas P., et al. AIDS 2015, 29:
25 Renal Dysfn DTG inhibits creatinine secretion, increasing creatinine levels, but does not affect egfr Mean Change From Baseline of Creatinine (mg/dl) DTG 50 mg QD (n = 411) RAL 400 mg BID (n = 411) Change in Serum Creatinine, Change in CrCl, Mean (± SD) [1,2] Mean (± SD) [1] Mean Change From Baseline (ml/min) BL Wk Wk Baseline (mg/ml): DTG 0.85 vs RAL 0.85 Baseline (ml/min): DTG 125 vs RAL Raffi F, et al. Lancet. 2013;381: Curtis LD, et al. IAS Abstract TUPE282.
26 Renal Dysfn Data on file. Gilead Sciences, Inc.
27 HCV Coinf. Drug-drug Interactions between DAAs and ARVs
28 Cancer Makinson A., et al. J Thorac Oncol. 2010;5:
29 Women Pooled data from Phase III clinical trials Squires K., et al. 4th International Workshop on HIV and Women January 13-14, Washington DC
30 Women
31 Squires K, et al. IAS Abstract MOLBPE08. Reproduced with permission. Women HIV-1 RNA < 50 c/ml (%) EVG/COBI/TDF/FTC ATV/RTV + TDF/FTC n = Overall 100,000 > 100,000 HIV-1 RNA (copies/ml) Emergent Resistance Resistance analysis population Developed resistance mutations to study drugs 86 EVG/COBI/FTC/TD F (n = 289) ATV/RTV + TDF/FTC (n = 286) EVG/COBI/FTC/TDF superior to ATV/RTV + TDF/FTC Overall treatment difference 6.5% (95% CI: 0.4%-12.6%) No significant differences between arms in change from BL for egfr, spine or hip BMD, LDL or HDL cholesterol, total cholesterol to HDL ratio, or triglycerides Significantly greater increase in total cholesterol with EVG/COBI/TDF/FTC Lower rate of discontinuations due to AEs with EVG/COBI/TDF/FTC vs ATV/RTV + TDF/FTC (2.4% vs 7.0%)
32 Women
33 Condition WHO EACS 2016 GESIDA 2016 BHIVA 2016 IAS 2016 DHHS 2016 Late presenter Women > 50 y/o TB Coinf. HepB Coinf. HepC Coinf. Renal Dis. CVD or risk Dyslipidemias NC Disorders Cancer
34 Condition WHO EACS 2016 GESIDA 2016 BHIVA 2016 IAS 2016 DHHS 2016 Late presenter Women No AZT,ddI,d4T,NVP > 50 y/o TB Coinf. TDF/FTC + EFV o RAL ABC/3TC o TDF/FTC + EFV Alt: RAL o MVC TDF/FTC + EFV ALT: RAL o DTG ABC/3TC o TDF/FTC + EFV o RAL HepB Coinf. TDF + FTC o 3TC TDF +/- FTC o 3TC TDF/TAF TDF o TAF + FTC o 3TC HepC Coinf. ABC/3TC o TDF o TAF(+FTC) + RAL o DTG Renal Dis. ABC/3TC + ITRNN o INI o DRV/r No TDF, ATV ABC, No TDF CVD or risk Dyslipidemias NC Disorders No EFV Cancer RAL, Alt: DTG No RTV
35 Condition ECUADOR CHILE VENEZUELA COLOMBIA ARGENTINA BRAZIL MEXICO Late presenter Women > 50 y/o TB Coinf. HepB Coinf. HepC Coinf. Renal Dis. CVD or risk Dyslipidemias NC Disorders Cancer
36 Condition ECUADOR CHILE VENEZUELA COLOMBIA ARGENTINA BRASIL MÉXICO Late presenter TDF/3TC + RAL Women Same as males > 50 y/o TB Coinf. TDF/(3TC or FTC) + EFV TDF/FTC + EFV or NVP 2 ITRN + EFV or RAL TDF/3TC + EFV or RAL HepB Coinf. TDF/FTC TDF +/- FTC or 3TC TDF/FTC, TDF/3TC or TAF/FTC TDF/(FTC o 3TC) or TAF/FTC HepC Coinf. TDF/(3TC o FTC) + 3rd w/o DDI Renal Dis. ABC/3TC + EFV No TDF CVD or risk Dyslipidemias (ABC ó TDF)/Xtc + RAL (Alt: ATV/r or DRV/r) TDF/FTC+RAL o DRV/r or ATV/r TDF/FTC o ABC/3TC + RAL o MVC or ATV-400 Switch PI/r to EFV, NVP, RAL or TV ATV ± r o DRV/r, no AZT, ABC nor EFV NC Disorders Cancer
37 It s recommended that all ART be individualized basedon characteristics such as sex, age, coinfections, comorbidities, risk for DDI, baseline CD4 and VL, life styles and likelihood of adherence, and knowing that there is not an only ART régimen that fits all individuals.
38 Scenario 1st line Alternative Not recommended General recomm. Late presenter Pregnancy Women (TDF o TAF)/FTC o ABC/3TC + INSTI or EFV or RPV or ATV/r or DRV/r EFV, DTG, RAL, EVG/c/TDF/FTC ABC/3TC or TDF/FTC or 3TC + ATV/r or DRV/r or RAL TDF/ FTC+EVG/c, ABC/3TC+DTG DRV/r AZT/3TC + LPV/r or EFV or RPV ATV/r or ATV/c; DRV/r or DRV/c, EFV AZT, ddi, d4t, NVP Otros IP/r > 50 y/o INSTI, ATV/r, DRV/r, RPV EFV TB Coinfection TDF/FTC or ABC/3TC + EFV or RAL HepB Coinfection TDF/FTC, TDF/3TC or TAF/FTC NVP HepC Coinfection RAL or DTG NVP
39 Scenario 1st line Alternative Not recommended Renal Disease ABC + 3TC, RAL DTG, DRV/r CVD or high risk Dyslipidemias Neurocogn. Dis. Cancer TDF/FTC + RAL or DTG or RPV RPV/TDF/FTC or RAL or DTG Uncertain: INSTI, DRV/r, ABC/3TC? Individualize (DDI, Adv ev. etc.) TDF and fixed coformulations; LPV/r, ATV ABC, EVG/Cobi, IP/r EFV, IP/r, coform with cobicistat EFV, RPV
40
41 Trends in the use of ART regimens in LATAM,
42 Comparison of selection of 3rd agent in the 1st ART regimen between < and > 50 yo. New admissions, Grupo VIHCOL, ,0% 40,0% 38,2% 36,4% 35,0% 30,0% 25,0% 20,0% 15,8% 15,9% 14,5% 14,5% 12,7% 13,6% 15,0% 9,8% 8,2% 10,0% 2,2% 3,1% 2,7% 3,6% 5,0% 0,9% 0,7% 0,9% 1,8% 1,8% 2,7% 0,0% < 50 años > 50 años 60,0% 49,8% 50,0% 43,8% 40,0% 30,0% 20,0% 10,0% 0,0% 1,9% 11,6% 16,7% 10,9% 8,6% 10,7% 11,7% 4,3% 6,2% 2,9% 4,9% 6,2% 1,5% 1,1% 1,2% 2,5% 2,5% < 50 años > 50 años ,0% 50,0% 40,0% 50,6% 42,9% 30,0% 20,0% 10,0% 0,0% 8,4% 10,5% 12,2% 7,8% 8,7% 5,4% 7,5% 7,5% 6,1% 3,1% 4,8% 4,8% 6,8% 6,1% 1,3% 2,1% 2,0% 1,4% < 50 años > 50 años
43 And a simple question... (just for yourself) What would I be willing to take if I were HIV positive?...
44 What is needed to do? HIV infection is a chronic incurable condition. To provide each individual with the best treatment option requires: 1. Timely updates of national guidelines with the best quality evidence 2. A tireless interaction with the health regulatory authorities 3. A price strategy affordable for our countries (economy of scale) But above all: A strong conviction of who prescribes! Otherwise, we will continue to be simply academic!
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV Treatment Update 8/3/2015. When to Start. Disclosures
8/3/215 HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationKees Brinkman OLVG- Amsterdam The Netherlands
integrase inhibitors in clinical practice in the Netherlands HIV Clinical Forum 2018 Kees Brinkman OLVG- Amsterdam The Netherlands Disclosures relevant activities to dislose companies advisory boards Gilead
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationINDUCTION/MAINTENANCE Clinical Case
INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationA case, and some pharmacological considerations. from the perspective of a virologist. Anna Maria Geretti University of Liverpool, United Kingdom
A case, and some pharmacological considerations. from the perspective of a virologist Anna Maria Geretti University of Liverpool, United Kingdom 1 Case History: Mr RS 53-year-old male Diagnosed HIV positive
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationCNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz
CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz Question for the audience Do you think that any integrase inhibitor drug produce CNS adverse
More informationWhat next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More information2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationAntiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion
Slide 1 of 51 Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama
More informationBHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes
BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy START & other changes Contents Introduction & treatment aims Major changes When to start What to start BHIVA: what
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDisclosures. Goals/Format. Patient 1 12/8/18. Antiretroviral Therapy Management. Harry Lampiris: None. Gabriel Chamie: None.
Disclosures Antiretroviral Therapy Management Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 6, 2018 Harry Lampiris, MD, 1 Gabriel Chamie, MD, MPH 2 Susa Coffey, MD, 2 and Vivek
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationChronic complications of HIV infection. An update Pablo Tebas, MD
Activity Code TM809 Chronic complications of HIV infection. An update 2014 Pablo Tebas, MD Learning Objectives Upon completion of this presentation, learners should be better able to: Identify and update
More informationHepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF
Hepatitis C in HIV Coinfection Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Disclosures I have received research grant support to UCSF related to HCV from the following: Abbvie
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationARV Consolidated Guidelines 2015
ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationpost-croi 2018 nieuwe ontwikkelingen-art Kees Brinkman
post-croi 2018 nieuwe ontwikkelingen-art Kees Brinkman Disclosure Voor bijeenkomst mogelijk relevante relaties met bedrijven adviesraad Gilead Janssen MSD Viiv Bedrijfsnamen spreker virology education
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationAntiretroviral Therapy in Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy in 2013 Joel Gallant, MD, MPH Johns Hopkins University School of Medicine When to Start When to Start: DHHS Guidelines, February 2013 ART recommended for all HIV+ individuals to
More informationForecasting pipeline ARVs. Joseph Perriëns Sandeep Juneja Aastha Gupta
Forecasting pipeline ARVs Joseph Perriëns Sandeep Juneja Aastha Gupta Presently: lack of visibility causes a gap between demand and generic production for new drugs Patent Holder R&D Marketing 3-4 yrs
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More information